Protein Binder Toolbox for Studies of Solute Carrier Transporters.

Autor: Gelová Z; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria., Ingles-Prieto A; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria., Bohstedt T; Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Frommelt F; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria., Chi G; Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Chang YN; Nuvisan ICB GmbH, Berlin, Germany., Garcia J; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria., Wolf G; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria., Azzollini L; Axxam SpA, Bresso, Milano, Italy., Tremolada S; Axxam SpA, Bresso, Milano, Italy., Scacioc A; Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Hansen JS; Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Serrano I; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria., Droce A; Department of Chemistry and Bioscience, Aalborg University, Aalborg, Denmark., Bernal JC; Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany., Burgess-Brown NA; Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Carpenter EP; Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Dürr KL; Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Kristensen P; Department of Chemistry and Bioscience, Aalborg University, Aalborg, Denmark., Geertsma ER; Max Planck Institute of Molecular Cell Biology and Genetics, Dresden, Germany., Štefanić S; Nanobody Service Facility, University of Zurich, AgroVet-Strickhof, Eschikon, Switzerland., Scarabottolo L; Axxam SpA, Bresso, Milano, Italy., Wiedmer T; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria., Puetter V; Nuvisan ICB GmbH, Berlin, Germany., Sauer DB; Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Superti-Furga G; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria; Center for Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria. Electronic address: gsuperti@cemm.oeaw.ac.at.

Publikováno v: Journal of molecular biology [J Mol Biol] 2024 Aug 15; Vol. 436 (16), pp. 168665. Date of Electronic Publication: 2024 Jun 13.

Extracellular modulation of TREK-2 activity with nanobodies provides insight into the mechanisms of K2P channel regulation.

Autor: Rödström KEJ; Clarendon Laboratory, Department of Physics, University of Oxford, Oxford, UK.; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford, UK.; Centre for Medicines Discovery, University of Oxford, Oxford, UK.; Department of Biochemistry, University of Oxford, Oxford, UK., Cloake A; Clarendon Laboratory, Department of Physics, University of Oxford, Oxford, UK., Sörmann J; Clarendon Laboratory, Department of Physics, University of Oxford, Oxford, UK.; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford, UK., Baronina A; Centre for Medicines Discovery, University of Oxford, Oxford, UK., Smith KHM; Clarendon Laboratory, Department of Physics, University of Oxford, Oxford, UK.; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford, UK.; Department of Biochemistry, University of Oxford, Oxford, UK., Pike ACW; Centre for Medicines Discovery, University of Oxford, Oxford, UK., Ang J; Centre for Medicines Discovery, University of Oxford, Oxford, UK., Proks P; Clarendon Laboratory, Department of Physics, University of Oxford, Oxford, UK.; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford, UK., Schewe M; Institute of Physiology, Medical Faculty, Kiel University, Kiel, Germany., Holland-Kaye I; Department of Biochemistry, University of Oxford, Oxford, UK., Bushell SR; Centre for Medicines Discovery, University of Oxford, Oxford, UK., Elliott J; Clarendon Laboratory, Department of Physics, University of Oxford, Oxford, UK., Pardon E; Structural Biology Brussels, Vrije Universiteit Brussel, Brussels, Belgium.; VIB-VUB Center for Structural Biology, VIB, Brussels, Belgium., Baukrowitz T; Institute of Physiology, Medical Faculty, Kiel University, Kiel, Germany., Owens RJ; The Rosalind Franklin Institute, Harwell Campus, Didcot, UK.; Division of Structural Biology, University of Oxford, Oxford, UK., Newstead S; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford, UK.; Department of Biochemistry, University of Oxford, Oxford, UK.; OXION Initiative in Ion Channels and Disease, University of Oxford, Oxford, UK., Steyaert J; Structural Biology Brussels, Vrije Universiteit Brussel, Brussels, Belgium.; VIB-VUB Center for Structural Biology, VIB, Brussels, Belgium., Carpenter EP; Centre for Medicines Discovery, University of Oxford, Oxford, UK. lizcarpen1@gmail.com.; OXION Initiative in Ion Channels and Disease, University of Oxford, Oxford, UK. lizcarpen1@gmail.com., Tucker SJ; Clarendon Laboratory, Department of Physics, University of Oxford, Oxford, UK. stephen.tucker@physics.ox.ac.uk.; Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford, UK. stephen.tucker@physics.ox.ac.uk.; OXION Initiative in Ion Channels and Disease, University of Oxford, Oxford, UK. stephen.tucker@physics.ox.ac.uk.

Publikováno v: Nature communications [Nat Commun] 2024 May 16; Vol. 15 (1), pp. 4173. Date of Electronic Publication: 2024 May 16.

Structures of DPAGT1 explain glycosylation disease mechanisms and advance TB antibiotic design

Autor: Dong, YY, Wang, H, Pike, ACW, Cochrane, SA, Hamedzadeh, S, Wyszyński, FJ, Bushell, SR, Royer, SF, Widdick, DA, Sajid, A, Boshoff, HI, Park, Y, Lucas, R, Liu, W-M, Lee, SS, Machida, T, Minall, L, Mehmood, S, Belaya, K, Liu, W-W, Chu, A, Shrestha, L, Mukhopadhyay, SMM, Strain-Damerell, C, Chalk, R, Burgess-Brown, NA, Bibb, MJ, Barry, CE, Robinson, CV, Beeson, D, Davis, BG, Carpenter, EP

Publikováno v: Cell
Dong, Y Y, Wang, H, Pike, A C W, Cochrane, S A, Hamedzadeh, S, Wyszynski, F, Bushell, S, Royer, S F, Widdick, D A, Sajid, A, Boshoff, H I, Park, Y, Lucas, R, Liu, W-M, Lee, S S, Machida, T, Minall, L, Mehmood, S, Belaya, K, Liu, W-W, Chu, A, Shrestha, L, Mukhopadhyay, S M M, Strain-Damerell, C, Chalk, R, Burgess-Brown, N A, Bibb, M, Barry 3rd, C, Robinson, C, Beeson, D, Davis, B & Carpenter, E P 2018, ' Structures of DPAGT1 Explain Glycosylation Disease Mechanisms and Advance TB Antibiotic Design ', Cell, vol. 175, pp. 1045-1058 . https://doi.org/10.1016/j.cell.2018.10.037

Summary Protein N-glycosylation is a widespread post-translational modification. The first committed step in this process is catalysed by dolichyl-phosphate N-acetylglucosamine-phosphotransferase DPAGT1 (GPT/E.C. 2.7.8.15). Missense DPAGT1 variants c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::6d9917953453a97d263ef06d74a47569
https://ora.ox.ac.uk/objects/uuid:515d9416-1e72-4e91-87e4-39eb4f426368

The structural basis of fatty acid elongation by the ELOVL elongases.

Autor: Nie L; Structural Genomics Consortium, Centre for Medicines Discovery, University of Oxford, Oxford, UK.; CRELUX GmbH, Planegg-Martinsried, Germany., Pascoa TC; Structural Genomics Consortium, Centre for Medicines Discovery, University of Oxford, Oxford, UK., Pike ACW; Structural Genomics Consortium, Centre for Medicines Discovery, University of Oxford, Oxford, UK., Bushell SR; Structural Genomics Consortium, Centre for Medicines Discovery, University of Oxford, Oxford, UK.; Orbit Discovery, Oxford, UK., Quigley A; Membrane Protein Laboratory, Diamond Light Source Ltd, Harwell Science and Innovation Campus, Didcot, UK.; Research Complex at Harwell, Harwell Science and Innovation Campus, Didcot, UK., Ruda GF; Structural Genomics Consortium, Centre for Medicines Discovery, University of Oxford, Oxford, UK.; Evotec Ltd, Milton, Abingdon, UK., Chu A; Structural Genomics Consortium, Centre for Medicines Discovery, University of Oxford, Oxford, UK.; Department of Biochemistry, Oxford University, Oxford, UK., Cole V; Structural Genomics Consortium, Centre for Medicines Discovery, University of Oxford, Oxford, UK.; Genomics Centre, South African Medical Research Council, Cape Town, South Africa., Speedman D; Structural Genomics Consortium, Centre for Medicines Discovery, University of Oxford, Oxford, UK., Moreira T; Structural Genomics Consortium, Centre for Medicines Discovery, University of Oxford, Oxford, UK., Shrestha L; Structural Genomics Consortium, Centre for Medicines Discovery, University of Oxford, Oxford, UK., Mukhopadhyay SMM; Structural Genomics Consortium, Centre for Medicines Discovery, University of Oxford, Oxford, UK., Burgess-Brown NA; Structural Genomics Consortium, Centre for Medicines Discovery, University of Oxford, Oxford, UK., Love JD; Albert Einstein College of Medicine, Department of Biochemistry, Bronx, NY, USA.; Novo Nordisk A/S, Måløv, Denmark., Brennan PE; Structural Genomics Consortium, Centre for Medicines Discovery, University of Oxford, Oxford, UK.; Alzheimer's Research UK Oxford Drug Discovery Institute, Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK., Carpenter EP; Structural Genomics Consortium, Centre for Medicines Discovery, University of Oxford, Oxford, UK. liz.carpenter@cmd.ox.ac.uk.; Vertex Pharmaceuticals Ltd, Milton, Abingdon, UK. liz.carpenter@cmd.ox.ac.uk.

Publikováno v: Nature structural & molecular biology [Nat Struct Mol Biol] 2021 Jun; Vol. 28 (6), pp. 512-520. Date of Electronic Publication: 2021 Jun 10.

ABCB10 exports mitochondrial biliverdin, driving metabolic maladaptation in obesity.

Autor: Shum M; Department of Medicine, Division of Endocrinology, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA.; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA.; Molecular Biology Institute at UCLA, 611 Charles E. Young Drive East, Los Angeles, CA 90095-1570, USA., Shintre CA; Center for Medicines Discovery, University of Oxford, Oxfordshire OX3 7DQ, UK., Althoff T; Department of Physiology, University of California, Los Angeles, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA., Gutierrez V; Department of Medicine, Division of Endocrinology, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA.; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA.; Molecular Biology Institute at UCLA, 611 Charles E. Young Drive East, Los Angeles, CA 90095-1570, USA., Segawa M; Department of Medicine, Division of Endocrinology, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA.; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA.; Molecular Biology Institute at UCLA, 611 Charles E. Young Drive East, Los Angeles, CA 90095-1570, USA., Saxberg AD; Department of Molecular Cell Biology, School of Natural Sciences, University of California, Merced, 5200 North Lake Rd., Merced, CA 95343, USA., Martinez M; Department of Molecular Cell Biology, School of Natural Sciences, University of California, Merced, 5200 North Lake Rd., Merced, CA 95343, USA., Adamson R; Center for Medicines Discovery, University of Oxford, Oxfordshire OX3 7DQ, UK., Young MR; Center for Medicines Discovery, University of Oxford, Oxfordshire OX3 7DQ, UK., Faust B; Center for Medicines Discovery, University of Oxford, Oxfordshire OX3 7DQ, UK., Gharakhanian R; Department of Medicine, Division of Endocrinology, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA.; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA.; Molecular Biology Institute at UCLA, 611 Charles E. Young Drive East, Los Angeles, CA 90095-1570, USA., Su S; Evans Biomedical Research Center, Boston University School of Medicine, 650 Albany St., Boston, MA 02118, USA., Chella Krishnan K; Department of Human Genetics, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA.; Department of Pharmacology and Systems Physiology, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267-0575, USA., Mahdaviani K; Department of Medicine, Division of Endocrinology, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA.; Evans Biomedical Research Center, Boston University School of Medicine, 650 Albany St., Boston, MA 02118, USA., Veliova M; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA., Wolf DM; Department of Medicine, Division of Endocrinology, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA.; Evans Biomedical Research Center, Boston University School of Medicine, 650 Albany St., Boston, MA 02118, USA., Ngo J; Department of Medicine, Division of Endocrinology, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA.; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA.; Molecular Biology Institute at UCLA, 611 Charles E. Young Drive East, Los Angeles, CA 90095-1570, USA.; Department of Chemistry and Biochemistry, University of California, Los Angeles, Los Angeles, CA 90095, USA., Nocito L; Evans Biomedical Research Center, Boston University School of Medicine, 650 Albany St., Boston, MA 02118, USA., Stiles L; Department of Medicine, Division of Endocrinology, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA.; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA., Abramson J; Department of Physiology, University of California, Los Angeles, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA., Lusis AJ; Department of Human Genetics, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA.; Department of Medicine, Division of Cardiology, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA.; Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA., Hevener AL; Department of Medicine, Division of Endocrinology, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA., Zoghbi ME; Department of Molecular Cell Biology, School of Natural Sciences, University of California, Merced, 5200 North Lake Rd., Merced, CA 95343, USA., Carpenter EP; Center for Medicines Discovery, University of Oxford, Oxfordshire OX3 7DQ, UK., Liesa M; Department of Medicine, Division of Endocrinology, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA. mliesa@mednet.ucla.edu.; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, 650 Charles E. Young Dr., Los Angeles, CA 90095, USA.; Molecular Biology Institute at UCLA, 611 Charles E. Young Drive East, Los Angeles, CA 90095-1570, USA.

Publikováno v: Science translational medicine [Sci Transl Med] 2021 May 19; Vol. 13 (594).